ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1922

TNF-α and IL-6 Induced Upregulation of CCR5 and CXCR3 Participate in Vδ2 Chemotaxis in RA

Wenxiu MO1, Shanshan YIN1, Chen ZHOU1 and Xuan Zhang2, 1Department of Rheumatology, Peking Union Medical College Hospital, Beijing, China, 2Peking Union Medical College Hospital, Beijing, China

Meeting: 2016 ACR/ARHP Annual Meeting

Date of first publication: September 28, 2016

Keywords: inflammatory cytokines and rheumatoid arthritis (RA)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, November 14, 2016

Title: T Cell Biology and Targets in Autoimmune Disease - Poster Session I

Session Type: ACR Poster Session B

Session Time: 9:00AM-11:00AM

Background/Purpose:  Vδ2T cells, a subpopulation of γδ T cells with inflammatory features, play a vital role in inflammation, tumor immunology, infectious disease and autoimmunity. However, the role of Vδ2 T cells in the pathogenesis of rheumatoid arthritis remains elusive.

Methods: 68 patients with rheumatoid arthritis, 21 patients with osteoarthritis and 21 healthy controls were enrolled in the study. All RA patients fulfilling the 2010 ACR/EULAR criteria for RA. Peripheral Vδ2T population, apoptosis, proliferation, chemokine receptor expression and pro-inflammatory cytokine secretion were quantified by flow cytometry. The infiltration of Vδ2 T cells within synovium was examined by immunohistochemistry and flow cytometry. The effect of TNF-α and IL-6 on Vδ2 T migration was determined by flow cytometry and transwell migration assay.

Results:  The percentage of peripheral Vδ2T cells of active RA were significantly decreased compared with healthy controls (1.80±1.76% vs 5.68±2.72%), which were negatively correlated with the disease activity indexes including DAS28(r=-0.6341, p<0.01), CRP(r=-0.4352, p<0.01) and ESR(r=-0.4364, p<0.01). However, the Vδ2T cells infiltrated in the synovium of RA were increased compared with OA (p<0.05). Comparing with OA Vδ2T cells, both peripheral and synovium Vδ2T cells of RA produced higher level of IFN-γ and IL-17 (p<0.05). The chemokine receptor CCR5 and CXCR3 expressed on Vδ2T cells in RA were significantly higher than HC and OA patients (p<0.05), which were induced by TNF-α and IL-6. TNF-α antagonist therapy restored the peripheral Vδ2 T cell in RA.

Conclusion: Elevated TNF-α and IL-6 in RA patients induced high expression of CCR5 and CXCR3 on Vδ2T cells, which subsequently promote Vδ2 T cells infiltrate into synovium and play an important role in the pathogenesis of RA. Vδ2 T cell is a promising potential biomarker and therapeutic target of RA.


Disclosure: W. MO, None; S. YIN, None; C. ZHOU, None; X. Zhang, None.

To cite this abstract in AMA style:

MO W, YIN S, ZHOU C, Zhang X. TNF-α and IL-6 Induced Upregulation of CCR5 and CXCR3 Participate in Vδ2 Chemotaxis in RA [abstract]. Arthritis Rheumatol. 2016; 68 (suppl 10). https://acrabstracts.org/abstract/tnf-%ce%b1-and-il-6-induced-upregulation-of-ccr5-and-cxcr3-participate-in-v%ce%b42-chemotaxis-in-ra/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2016 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/tnf-%ce%b1-and-il-6-induced-upregulation-of-ccr5-and-cxcr3-participate-in-v%ce%b42-chemotaxis-in-ra/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology